CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue:
Genetic testing	$ 439,400	$ 411,557	$ 1,342,947	$ 1,744,342
Other	32,751	7,484	145,365	14,220
Total revenue	472,151	419,041	1,488,312	1,758,562
Cost of revenue	358,578	362,769	1,115,095	1,242,757
Gross profit	113,573	56,272	373,217	515,805
Operating expenses:
Research and development	242,142	161,353	666,839	509,509
Selling, general and administrative	1,305,583	2,035,179	4,338,245	4,610,737
Amortization of intangibles	23,525	27,317	70,575	81,950
Total operating expenses	1,571,250	2,223,849	5,075,659	5,202,196
Loss from operations	(1,457,677)	(2,167,577)	(4,702,442)	(4,686,391)
Other income (expense):
Interest income	911	2,488	4,511	4,628
Interest expense	0	(10,968)	0	(472,185)
Total other income (expense)	911	(8,480)	4,511	(467,557)
Loss before income taxes	(1,456,766)	(2,176,057)	(4,697,931)	(5,153,948)
Benefit for income taxes	0	0	0	0
Net loss	$ (1,456,766)	$ (2,176,057)	$ (4,697,931)	$ (5,153,948)
Basic and diluted net loss per common share	$ (0.01)	$ (0.02)	$ (0.04)	$ (0.06)
Weighted average common shares outstanding, basic and diluted	122,548,292	122,277,324	122,515,671	79,666,229